Stockscreener 앱 받기
2.71
3.90%
-0.11
시장 영업 전:
2.74
0.03
+1.11%
전일 마감가:
$2.82
열려 있는:
$2.76
하루 거래량:
9.70M
Relative Volume:
1.09
시가총액:
$2.56B
수익:
$1.31M
순이익/손실:
$-597.65M
주가수익비율:
-2.7938
EPS:
-0.97
순현금흐름:
$-425.62M
1주 성능:
+12.68%
1개월 성능:
-6.55%
6개월 성능:
-25.14%
1년 성능:
-30.15%
1일 변동 폭
$2.64
$2.79
1주일 범위
$2.38
$2.94
52주 변동 폭
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
명칭
Immunitybio Inc
전화
(844) 696-5235
주소
3530 JOHN HOPKINS COURT, SAN DIEGO
IBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.71 | 2.67B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 개시 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | BTIG Research | Buy |
| 2023-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 개시 | Jefferies | Buy |
Immunitybio Inc 주식(IBRX)의 최신 뉴스
RSI + MACD Show Convergence for ImmunityBio Inc.2025 Price Targets & Growth Focused Stock Pick Reports - sundaytimes.kr
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - Insider Monkey
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment - TipRanks
Why ImmunityBio (IBRX) Is Up 18.5% After Early VA Uptake of ANKTIVA and Improving Financials - simplywall.st
ImmunityBio higher after early-stage trial results for cell therapy in lymphoma - MSN
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy - BioSpace
ImmunityBio stock surges on promising trial results for lymphoma treatment, analysts forecast significant upside potential. - AInvest
ImmunityBio Shares Rise After 'Promising' Results From Lymphoma Treatment - MarketScreener
ImmunityBio Surges 15% on Groundbreaking Cancer Trial Results: A New Era for NK Cell Therapy? - AInvest
ImmunityBio’s Q2 Earnings Surge Due to ANKTIVA Success - StocksToTrade
ImmunityBio Stock Surges on Robust Q2 Earnings Report - timothysykes.com
Immunitybio stock soars after promising cancer therapy trial results By Investing.com - Investing.com Canada
ImmunityBio's NK cell therapy shows promise in lymphoma trial. - AInvest
ImmunityBio up on trial data for cell therapy (IBRX:NASDAQ) - Seeking Alpha
CD19 CAR-NK therapy shows complete responses in late-stage lymphoma - Investing.com Canada
Immunitybio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free - MarketScreener
VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - precisionvaccinations.com
ImmunityBio shares rise 1.21% premarket after ANKTIVA treatment approval for bladder cancer. - AInvest
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Business Wire
ImmunityBio’s Shareholder Settlement Gains Preliminary Approval - The Globe and Mail
ImmunityBio Shareholder Settlement Gains Preliminary Approval, Boosting Company's Future Prospects - AInvest
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Why Investors Shouldn't Be Surprised By ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Q2 2025 Revenue Up 5% YoY to $1,241mln; Raises FY23 Guidance, Innovation Target. - AInvest
ImmunityBio Q2 Earnings Show 60% Revenue Growth, $153.7 Million in Cash, and Strong Sales Momentum. - AInvest
ImmunityBio's ANKTIVA Receives Buy Rating Amid Expanding Oncology Potential and Market Growth - AInvest
ImmunityBio Reports Q2 Earnings with 60% Revenue Increase, $43M in Sales, and 246% Unit Growth - AInvest
ImmunityBio 2025 Q2 Earnings Sustained Losses Amid Strong Revenue Surge - AInvest
ImmunityBio Reports Revenue Growth Amidst Continued Investments - TipRanks
ImmunityBio: Q2 Earnings Snapshot - Norwalk Hour
ImmunityBio’s Revenue Jumps On Bladder Cancer Drug Success - Finimize
ImmunityBio's Q2 Net Loss Narrows, Revenue Rises - MarketScreener
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
ImmunityBio: Boral Capital raises PT to $30, maintains Buy rating. - AInvest
ImmunityBio Q2 Financial Results: $92.6 Million LossNews and Statistics - IndexBox
Immunitybio Inc earnings beat, revenue topped estimates By Investing.com - Investing.com India
ImmunityBio, Inc. SEC 10-Q Report - TradingView
Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.10 a Share, vs. FactSet Est of $0.11 Loss - MarketScreener
Immunitybio Inc earnings beat, revenue topped estimates - Investing.com
ImmunityBio Q2 revenue up 60%, surpassing market estimates, on strong sales of ANKTIVA - MarketScreener
Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $26.4M, vs. FactSet Est of $23.1M - MarketScreener
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code - Yahoo Finance
ImmunityBio (IBRX) Announces Preliminary Financial Results for the Quarter Ended June 30 - MSN
Watch for Trend Continuation in ImmunityBio Inc. Next WeekCapital Growth With Controlled Risk Picks Suggested - beatles.ru
ImmunityBio Inc. Moves Into Overbought Range Analysts CautiousReal-Time Market Sentiment Tracking Gains Momentum - metal.it
What are the technical indicators suggesting about ImmunityBio Inc.Consistent high-performance stocks - Jammu Links News
What is the dividend policy of ImmunityBio Inc. stockInvest smarter with daily stock recommendations - Jammu Links News
Is ImmunityBio Inc. a growth stock or a value stockFree Stock Market Real-Time Monitoring - Jammu Links News
How strong is ImmunityBio Inc. company’s balance sheetGet exclusive market insights for better trading - Jammu Links News
10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey
Immunitybio Inc (IBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
1.56%
자본화:
|
볼륨(24시간):